Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

delavirdine (Rx)Brand and Other Names:Rescriptor

 
 
 

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

tablet

  • 100mg
  • 200mg
more...

HIV-1 Infection

400 mg PO TID with other antiretrovirals

Solution administration

  • Add 100 mg-tablets (4 tablets totaling 400 mg) in at least 3 oz water; allow to stand for few minutes
  • Do NOT use 200 mg tablets (not well-dispersed in water)
  • Stir slurry until mixed uniformly; consume promptly
  • Rinse glass with water and swallow entire contents of rinse

Other Information

Used in combination with at least 2 other antiretroviral agents

<16 years old: Safety and efficacy not established

Next

Interactions

Interaction Checker

delavirdine and

No Results

     
     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            Sort by :  
             activity indicator 
            Previous
            Next

            Adverse Effects

            >10%

            Rash (32-35%)

            1-10%

            Headache

            Fatigue

            Pruritus

            Diarrhea

            Vomiting

            Increased ALT/AST

            Previous
            Next

            Warnings

            Black Box Warnings

            Indicated for use only in combination with appropriate antiretroviral drugs

            Resistant virus emerges rapidly when delavirdine is administered as monotherapy

            Contraindications

            Hypersensitivity

            Coadministration with drugs highly dependent on CYP3A4 for clearance and those for which elevated plasma levels are associated with serious or life-threatening events (eg, dihydroergotamine, ergonovine, ergotamine, methylergonovine, cisapride, pimozide, alprazolam, midazolam, triazolam)

            Coadministration with drugs (eg, CYP inducers) where significant decreases in delavirdine plasma concentrations may occur, which may result in loss of virologic response and possible resistance and cross-resistance to other NNRTIs

            Cautions

            Use only in combination with other agents - delavirdine alone results in rapid resistance

            Patients with achlorhydria should take with acidic juice

            Avoid antacids 1 hr prior to and after administration

            Discontinue if severe rash or rash with associated mucocutaneous lesions; erythema multiforme and Stevens-Johnson Syndrome

            Avoid St John's wort: may result in loss of virologic response/resistance

            Hepatic impairment

            Risk of cross resistance to other NNRTI

            Risk of immune reconstitution syndrome if used in combination with other antiretroviral drugs

            Previous
            Next

            Pregnancy & Lactation

            Pregnancy Category: C

            Lactation: Not known whether distributed into milk. Because of both the potential for HIV transmission and the potential for serious adverse reactions in nursing infants, mothers should be instructed not to breastfeed.

            Health professionals should contact the antiretroviral pregnancy registry to monitor outcomes of pregnant women exposed to delavirdine or other antiretroviral medications by calling 1-800-258-4263 or going to www.APRegistry.com.

            Pregnancy Categories

            A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA:Information not available.

            more...
            Previous
            Next

            Pharmacology

            Absorption: rapid

            Distribution: low concentration in saliva & semen; CSF 0.4% concurrent plasma concentration

            Protein Bound: ~98%, primarily albumin

            Bioavailability: 85%; ~20% incr w/ slurry

            Half-life: 5.8 hr (mean)

            Peak Plasma Time: 1 hr

            Metabolism: hepatic via CYP3A4 & 2D6

            Excretion: urine (51%, <5% as unchanged drug); feces (44%)

            Mechanism of Action

            Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) of HIV-1

            Directly binds to reverse transcriptase and inhibits RNA- & DNA-dependent DNA polymerase

            Previous
            Next

            Images

            Previous
            Next

            Formulary

            FormularyPatient Discounts

            To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

            Adding plans allows you to:

            • View the formulary and any restrictions for each plan.
            • Manage and view all your plans together – even plans in different states.
            • Compare formulary status to other drugs in the same class.
            • Access your plan list on any device – mobile or desktop.

            The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

            Tier Description
            1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
            2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
            3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
            4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            NC NOT COVERED – Drugs that are not covered by the plan.
            Code Definition
            PA Prior Authorization
            Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
            QL Quantity Limits
            Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
            ST Step Therapy
            Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
            OR Other Restrictions
            Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
            Add or Remove Plans
            Plans for
            Select State:
            Non-Medicare PlansMedicare Plans

            Select a box to add or remove a plan.

            Select a class to view formulary status for similar drugs

            Additional Offers
            Email to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Email Forms to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Previous
             
             
             
            All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.